679 related articles for article (PubMed ID: 28958851)
1. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.
Halawi H; Khemani D; Eckert D; O'Neill J; Kadouh H; Grothe K; Clark MM; Burton DD; Vella A; Acosta A; Zinsmeister AR; Camilleri M
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):890-899. PubMed ID: 28958851
[TBL] [Abstract][Full Text] [Related]
2. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
van Can J; Sloth B; Jensen CB; Flint A; Blaak EE; Saris WH
Int J Obes (Lond); 2014 Jun; 38(6):784-93. PubMed ID: 23999198
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
[TBL] [Abstract][Full Text] [Related]
5. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy.
Acosta A; Camilleri M; Shin A; Vazquez-Roque MI; Iturrino J; Burton D; O'Neill J; Eckert D; Zinsmeister AR
Gastroenterology; 2015 Mar; 148(3):537-546.e4. PubMed ID: 25486131
[TBL] [Abstract][Full Text] [Related]
6. Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.
Maselli D; Atieh J; Clark MM; Eckert D; Taylor A; Carlson P; Burton DD; Busciglio I; Harmsen WS; Vella A; Acosta A; Camilleri M
Obesity (Silver Spring); 2022 Aug; 30(8):1608-1620. PubMed ID: 35894080
[TBL] [Abstract][Full Text] [Related]
7. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.
Kadouh H; Chedid V; Halawi H; Burton DD; Clark MM; Khemani D; Vella A; Acosta A; Camilleri M
J Clin Endocrinol Metab; 2020 May; 105(5):1552-63. PubMed ID: 31665455
[TBL] [Abstract][Full Text] [Related]
9. Relationship of gastric emptying or accommodation with satiation, satiety, and postprandial symptoms in health.
Halawi H; Camilleri M; Acosta A; Vazquez-Roque M; Oduyebo I; Burton D; Busciglio I; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G442-G447. PubMed ID: 28774870
[TBL] [Abstract][Full Text] [Related]
10. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL
Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
[TBL] [Abstract][Full Text] [Related]
12. Effect of the GLP-1 analog liraglutide on satiation and gastric sensorimotor function during nutrient-drink ingestion.
Rotondo A; Janssen P; Mulè F; Tack J
Int J Obes (Lond); 2013 May; 37(5):693-8. PubMed ID: 22846777
[TBL] [Abstract][Full Text] [Related]
13. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.
Chedid V; Vijayvargiya P; Carlson P; Van Malderen K; Acosta A; Zinsmeister A; Camilleri M
Neurogastroenterol Motil; 2018 Jul; 30(7):e13313. PubMed ID: 29488276
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
15. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people.
Vazquez Roque MI; Camilleri M; Stephens DA; Jensen MD; Burton DD; Baxter KL; Zinsmeister AR
Gastroenterology; 2006 Dec; 131(6):1717-24. PubMed ID: 17087952
[TBL] [Abstract][Full Text] [Related]
16. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
Horowitz M; Flint A; Jones KL; Hindsberger C; Rasmussen MF; Kapitza C; Doran S; Jax T; Zdravkovic M; Chapman IM
Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
[TBL] [Abstract][Full Text] [Related]
17. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
18. Effect of a cellulose-containing weight-loss supplement on gastric emptying and sensory functions.
Berthold HK; Unverdorben S; Degenhardt R; Unverdorben M; Gouni-Berthold I
Obesity (Silver Spring); 2008 Oct; 16(10):2272-80. PubMed ID: 18719632
[TBL] [Abstract][Full Text] [Related]
19. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Astrup A; Rössner S; Van Gaal L; Rissanen A; Niskanen L; Al Hakim M; Madsen J; Rasmussen MF; Lean ME;
Lancet; 2009 Nov; 374(9701):1606-16. PubMed ID: 19853906
[TBL] [Abstract][Full Text] [Related]
20. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
Flint A; Kapitza C; Hindsberger C; Zdravkovic M
Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
